Tags : ranibizumab

Genentech Reports Results of Port Delivery System with Ranibizumab in

Shots: The P-III Archway study involves assessing of PDS with ranibizumab, refilled @6mos. at fixed intervals, vs ranibizumab (0.5mg, monthly IVT) in 418 patients with nAMD, prior treated with VEGF therapy Results: 98.4% of PDS patients were able to go 6mos. without needing additional treatment and achieved vision outcomes equivalent to patients receiving ranibizumab (0.5mg, […]Read More

Roche Reports Results of Port Delivery System with Ranibizumab in

Shots: The P-III Archway study involves assessing the efficacy and safety of Port Delivery System with ranibizumab (PDS), refilled q6w at fixed intervals vs monthly IVT of ranibizumab (0.5mg) in 418 people with nAMD The P-III Archway study resulted in meeting its 1EP i.e. patients achieved visual acuity outcomes equivalent and is well tolerated with […]Read More

Bausch + Lomb Signs an Exclusive License Agreement with STADA

Shots: STADA and Xbrane to receive up front and milestones upon approval and launch of the Xlucane in the US and will be eligible to get an equal share of profits from sales of the biosimilar. The companies aim to obtain all currently approved indications for Lucentis in the US and Canada Xbrane and STADA […]Read More

Coherus Signs an Exclusive License Agreement with Bioeq for Biosimilar

Shots: Bioeq to receive up front, regulatory and launch milestones with equal profit sharing. Coherus to get exclusive rights to commercialize biosimilar candidate referencing Genentech’s Lucentis with its anticipated launch in 2021 in the US Bioeq will be responsible for product delivery to the Coherus and will submit BLA to the US FDA in Q4’19 […]Read More